Small study checks kidney and race impact on transplant drug
NCT ID NCT05534620
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how kidney function and race/ethnicity affect the drug treosulfan in 20 patients with AML or MDS getting a stem cell transplant. The goal was to find safe doses for those with kidney problems. It was a small, early-phase study that did not test a new treatment, but gathered important safety information.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
University of Illinois
Chicago, Illinois, 60612, United States
-
VCU Massey Cancer Center
Richmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill targets genetic weakness in Hard-to-Treat blood cancers
- New hope for AML patients: experimental drug IPN60340 enters key trial
- New transplant cocktail aims to tame blood cancer without severe side effects
- Experimental drug tested for Post-Transplant blood cancers — but study halted early
- Massive study aims to beat deadly fungus in transplant patients
- New drug cocktail shows promise for rare blood cancer